Angiogenesis-related endothelial receptors and extracellular matrix components

Angiogenesis-related endothelial receptors and extracellular matrix (ECM) components comprise a broad set of molecular targets involved in the physiological and pathological formation of new blood vessels. This category includes key signaling receptors such as Vascular Endothelial Growth Factor Receptors (VEGFR-1, -2, and -3) and the Tie family (Tie-1 and Tie-2), which are essential for endothelial cell activation and survival (Source: UniProt). It also encompasses ECM elements like integrins (e.g., αvβ3), matrix metalloproteinases (MMPs), and basement membrane proteins that provide structural support and modulate growth factor bioavailability (Source: PubMed, PMID: 25611106). In diseases such as cancer and age-related macular degeneration, these components are often upregulated to facilitate tumor vascularization or abnormal vessel leakage (Source: NIH/NCI). Therapeutic interventions, such as bevacizumab (targeting VEGF) and ramucirumab (targeting VEGFR2), aim to disrupt these pathways to inhibit disease progression. However, because these targets are also involved in normal vascular homeostasis, their inhibition can lead to significant adverse effects like hypertension, proteinuria, and impaired wound healing (Source: StatPearls).

Other names

Angiogenic targetsVascular endothelial targetsPro-angiogenic receptors and matrix factorsEndothelial cell surface receptors and ECM components

Inhibition of pro-angiogenic signaling by blocking ligand-receptor interactions, inhibiting intracellular kinase activity, or disrupting extracellular matrix-mediated adhesion and remodeling.